INTERCEPT goes beyond to protect patients*, improve availability, and deliver value.
The INTERCEPT Blood System protects patients through broad-spectrum transfusion-transmitted infection (TTI) risk reduction with the inactivation of bacteria, viruses, protozoans, and leukocytes.1,2 Blood components are available earlier, resulting in fresher platelets that may be transfused sooner,3,4 and improving availability of fibrinogen† and other vital clotting factors when minutes matter.5 Economic and operational efficiencies are gained through waste and cost reduction associated with testing and TTI risks.6-8
Protect Patients*
Improve Availability
Deliver Value
INTERCEPT® Blood System for Platelets
Pathogen Reduction System
Pathogen Reduced Cryoprecipitated Fibrinogen Complex
INTERCEPT® Fibrinogen Complex (IFC)
What’s New
The PIPER Phase IV Study: Assessing the Safety of Pathogen Reduced Platelets in a Large Study of Platelet Transfusion-Associated Pulmonary Injury
Dr. Allison Wheeler of the University of Washington School of Medicine describes the largest Phase IV prospective study of platelet transfusion-associated pulmonary injury to-date, with over 10,000 conventional and PR platelet units transfused to hematology-oncology patients. Outcomes included incidence of treatment-emergent acute respiratory distress syndrome (TE-ARDS), adverse events, and blood component utilization.
Resources
Learn More
Find out more about pathogen reduced blood components.
*There is no pathogen inactivation process that has been shown to eliminate all pathogens. Certain non-enveloped viruses (e.g., HAV, HEV, B19 and poliovirus) and Bacillus cereus spores have demonstrated resistance to the INTERCEPT process. For a full list of pathogens, please refer to package inserts. †INTERCEPT Fibrinogen Complex is available for immediate use for up to 5 days when stored thawed; and when stored frozen requires thawing prior to use.
- The INTERCEPT Blood System for Platelets Package Insert, Cerus Corporation.
- INTERCEPT Blood System for Cryoprecipitation for the manufacturing of Pathogen Reduced Cryoprecipitated Fibrinogen Complex Package Insert.
- Collier, T. and Chrebtow , V. “Impact of Pathogen Reduction (PR) vs. LVDS Testing on Platelet Availability: A Study Based on Real-World Experience.” AABB 2022. Poster P-IV-8.
- Prichard, A.B., et al. “Comparing Usable Shelf-Life of Pathogen Reduced Platelets vs. LVDS Screened Platelets”. AABB 2022. Poster P-IV-2.
- Meyer DE, et al. The Journal of Trauma and Acute Care Surgery 2017;83:19-24.
- Harm SK, et al. Transfusion. 2018 Apr; 58(4):938-942.
- Ruby KN, et al. Transfusion. 2018 Jul; 58(7):1665-1669.
- Cerus Corporation. (2022) “Assessing Impact of INTERCEPT Fibrinogen Complex (IFC) on Wastage and Massive Transfusion Protocols (MTPs)”. [Case Study].